Specific mutations occurring in certain cellular genes(proto- oncogenes) may be important in the initiation and development of human cancers. Point mutations that occur in various members of the ras family of proto-oncogenes have been extensively studied and may be present in some 10-30% of various human malignancies. Despite the extraordinary research interest in such ras mutations, a rigorous, comprehensive study relating such point mutations to stage and development of the malignancy, response to chemotherapy, and prognosis has not been performed in any human cancer. This proposal involves such a study of human myeloid leukemia, which has been reported to be associated with point mutations in the N-ras protooncogene in some 25-50% of cases. We have developed an experimental protocol for directly sequencing critical codons of the N-ras proto-oncogene. This approach is fast, requires relatively few cells, and is capable of screening a large number of samples. Using this protocol we will determine the following: 1. What is the frequency of N-ras mutations in acute and chronic myeloid leukemia? 2. At what stage in the development of the leukemia do such N-ras mutations occur? 3. Is there any correlation between the presence of such point mutations and the leukemic phenotype, response to chemotherapy, and overall prognosis? Although these proposed studies are restricted to human myeloid leukemia, nevertheless ras mutations may play a significant role in the development of many different types of human cancers. Thus these studies relating N-ras mutations to the multistage development and pathogenesis of human myeloid leukemia may also have direct relevance to the development of other types of human malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA040728-04
Application #
3181033
Study Section
Pathology B Study Section (PTHB)
Project Start
1985-07-01
Project End
1991-06-30
Budget Start
1988-07-01
Budget End
1989-06-30
Support Year
4
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Radich, J P; Kopecky, K J; Willman, C L et al. (1990) N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood 76:801-7
Andrews 3rd, D F; Collins, S J; Reddy, A L (1990) Absence of the c-Ha-ras codon 61 point mutation in murine solid tumors induced by subcutaneously applied 7,12-dimethylbenzanthracene. Cancer Lett 54:139-45
Collins, S J; Howard, M; Andrews, D F et al. (1989) Rare occurrence of N-ras point mutations in Philadelphia chromosome positive chronic myeloid leukemia. Blood 73:1028-32
Hickstein, D D; Back, A L; Collins, S J (1989) Regulation of expression of the CD11b and CD18 subunits of the neutrophil adherence receptor during human myeloid differentiation. J Biol Chem 264:21812-7
Collins, S J (1988) Direct sequencing of amplified genomic fragments documents N-ras point mutations in myeloid leukemia. Oncogene Res 3:117-23
Hickstein, D D; Howard, M; Meuller, L et al. (1988) Expression of the beta-subunit of the human leukocyte adherence receptor depends upon cell type and stage of differentiation. J Immunol 141:4313-7
Hickstein, D D; Hickey, M J; Collins, S J (1988) Transcriptional regulation of the leukocyte adherence protein beta subunit during human myeloid cell differentiation. J Biol Chem 263:13863-7
Andrews 3rd, D F; Collins, S J (1987) Heterogeneity in expression of the bcr-abl fusion transcript in CML blast crisis. Leukemia 1:718-24
Collins, S J; Groudine, M T (1987) Chronic myelogenous leukemia: amplification of a rearranged c-abl oncogene in both chronic phase and blast crisis. Blood 69:893-8
Collins, S; Coleman, H; Groudine, M (1987) Expression of bcr and bcr-abl fusion transcripts in normal and leukemic cells. Mol Cell Biol 7:2870-6

Showing the most recent 10 out of 11 publications